Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557943 | 1.00 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDCYP11B1 | |
| SCHEMBL7569997 | 0.90 | BACE1 (0.35) | BACE1BACE2CYP11B1CYP11B2 | |
| SCHEMBL7570297 | 0.90 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDDYRK1A | |
| SCHEMBL13081366 | 0.90 | BACE1 (0.33) | BACE1 | |
| SCHEMBL8213822 | 0.90 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDDYRK1A | |
| SCHEMBL13055291 | 0.90 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDDYRK1A | |
| SCHEMBL13054355 | 0.89 | ZAP70 (0.31) | BACE1BACE2CTSD | |
| SCHEMBL7548774 | 0.89 | ZAP70 (0.31) | BACE1BACE2CTSD | |
| SCHEMBL13081561 | 0.88 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDDYRK1A | |
| SCHEMBL13081562 | 0.88 | BACE1 (0.34) | BACE1BACE2CYP3A4CTSDDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885BACE2 30/4885CYP3A4 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.